Monoclonal Antibodies in Children With Severe Anaemia or Severe Malaria to Prevent Malaria After Hospital Discharge

NCT07082205 | Recruiting Phase 3 DMC

• 3 other identifiers: LSTM REC: 24-020U01GH002290IAA#AAI24032-001-00000
• Study Type: interventional
• Target: 398
• Locations: 1 country
• Sites: 2

Brief Summary

Background and rationale: Hospitalised children with severe anaemia remain at high risk of dying or requiring hospital readmission for at least 6 months after discharge. In highly malaria-endemic settings, malaria is a major contributor to these post-discharge readmissions and deaths. In 2022, the World Health Organisation (WHO) recommended post-discharge malaria chemoprevention (PDMC) for children hospitalised with severe anaemia living in malarious areas. Kenya, together with several other countries in sub-Saharan Africa, aims to expand WHO's recommendation and introduce PDMC in children hospitalised with severe anaemia or severe malaria, including children with severe malaria who do not have severe anaemia (e.g. cerebral malaria). PDMC consists of full 3-day treatment courses with long-acting antimalarials given monthly three times after discharge. PDMC is very effective in clinical trials. However, adherence to these monthly 3-day drug treatments is limited under real-life conditions. Furthermore, PDMC provides chemoprevention for about 3.5 months only, while the risk of dying or needing to be readmitted remains high for several more months. The US National Institutes of Health (NIH) has developed two monoclonal antibodies targeting Plasmodium falciparum malaria (mMAb). These proteins specifically target a highly conserved epitope found on the circumsporozoite protein-1 (CSP-1) of P. falciparum to neutralize it and prevent malaria infection. A key feature of mMAbs is that they can provide protection for up to 6 months with a single dose and thus serve as a "long-acting" drug. Recent placebo-controlled studies in healthy adults in Mali suggest that the first mMAb, CIS43LS, when administered at a dose of 40 mg/kg intravenously (IV), can block 88% of malaria infections for at least 6 months. More recently, studies with a newer mMAb called L9LS, which is anticipated to be more potent than CIS43LS, showed a 74% reduction in uncomplicated clinical malaria by 6 months when administered subcutaneously to healthy Malian children aged 6-10 years by a single subcutaneous (SC) dose of 10-20 mg/kg (NCT05304611). Similar studies with L9LS are ongoing in healthy children under 5 years of age in Siaya, western Kenya (NCT05400655). Young children admitted to hospitals in highly malaria-endemic areas with severe anaemia or severe malaria are an ideal target group for passive immunoprevention with mMAbs as a single infusion with mMAb while in the hospital could protect this high-risk group during the entire vulnerable post-discharge period. Overview design: investigators will conduct a 2-arm, multi-centre, individually randomised, placebo-controlled non-inferiority trial in 398 children with severe malaria or severe anaemia. Children will be randomly assigned (1:1) using minimum sufficient balance (MSB) randomisation to receive either mMAb before discharge or 3 courses of monthly PDMC after discharge, according to WHO guidelines. The study will be placebo-controlled. Children in the PDMC arm will receive a placebo infusion with normal saline before discharge; children in the mMAb arm will receive placebo-PDMC. All children will receive standard in-hospital care, including a blood transfusion and treatment for severe malaria where indicated. They will also receive a full 3-day treatment course with the antimalarial artemether-lumefantrine (AL) to clear any existing malaria infections as soon as they have recovered and can take oral medication. The primary endpoint is the incidence of clinical malaria detected by passive case detection by 6 months post-discharge (the intervention period). Key secondary endpoints include the rates of readmissions and deaths (all children). Children will be followed for another 6 months (post-intervention period) to determine the duration of protection, any long-term impact (e.g., growth) and if mMAbs result in a delayed acquisition of natural protective immunity against clinical malaria Study Interventions: All children will receive standard in-hospital care, including a blood transfusion, antibiotics, and treatment for severe malaria where indicated. All children in both arms will be empirically treated for malaria infection around discharge with a 3-day regimen with artemether-lumefantrine to ensure parasite clearance of any existing parasites. Participants in the mMAb arm will receive the study agent L9LS IV with a target dose of 30 mg/kg. The IV dose will use 1 kg step increases. During the 6-month intervention period, children in the placebo-mMAbs arm will receive three courses of monthly PDMC as per WHO guidelines with dihydroartemisinin-piperaquine (DP) at 2, 6 and 10 weeks post-discharge. Those in the mMAbs arm will receive an identical placebo PDMC

Conditions

Malaria; Severe Malaria; Severe Anaemia; Post Discharge

Keywords

monoclonal antibodies; malaria; post-discharge; prevention; severe anaemia; severe malaria; children

Outcome Measures

Primary Outcomes (1)

• Incidence rate of clinical malaria from 3 to 26 weeks post-discharge

  Assess the efficacy of a single dose of L9LS versus PDMC against microscopy or RDT-confirmed clinical malaria in hospitalised children with severe anaemia or severe malaria. Clinical malaria defined as an illness accompanied by measured fever ≥37.5°C or a history of fever (subjective or objective) in the previous 24 hours, accompanied by any level of asexual parasitaemia detected by microscopy or RDT (pLDH or HRP2-band).

  3 to 26 weeks post-discharge

Secondary Outcomes (21)

• Number of participants with adverse events following a dose of L9LS versus PDMC in children hospitalised with severe anaemia or severe malaria

  From enrollment to12 months post-discharge

• Efficacy of a single dose of L9LS versus PDMC against the first or only microscopy or RDT-confirmed clinical malaria in children hospitalised with severe anaemia or severe malaria by 6 months post-discharge

  3-26 weeks post-discharge

• Efficacy of a single dose of L9LS versus PDMC against clinical malaria with parasite density >5,000/microlitre (3- 26 weeks post discharge)

  3-26 weeks post discharge (6 months)

• Efficacy of a single dose of L9LS versus PDMC against readmission for any reason in children hospitalised with severe anaemia or severe malaria by 6 months post-discharge

  3-26 weeks post-discharge (6 months)

• Efficacy of a single dose of L9LS versus PDMC on anaemia by 6 months post-discharge

  6 months post discharge

Other Outcomes (11)

• The maximal observed blood concentration (Cmax) of a single dose of L9LS in children hospitalised with severe anaemia or severe malaria

  over 12 months post-discharge

• Effect of a single dose of L9LS versus PDMC on biomarkers of inflammation post-discharge in children hospitalised with severe anaemia or severe malaria

  Over 12 months post-discharge

• Effect of a single dose of L9LS versus PDMC on biomarkers of naturally acquired immunity post-discharge in children hospitalised with severe anaemia or severe malaria

  Over 12 months post-discharge

Study Arms (2)

Antimalarial monoclonal antibodies (mMAbs) -L9LS + Placebo-PDMC

EXPERIMENTAL

Participants in the mMAb arm will receive the study agent L9LS IV with a target dose of 30 mg/kg. The IV dose will use 1 kg step increases. They will also receive a course of PDMC-Placebo at 2, 6, and 10 weeks post-discharge

Biological: Antimalarial monoclonal antibodies; Drug: Placebo PDMC

Placebo-mMAB + Malaria chemoprevention- PDMC

ACTIVE COMPARATOR

mMAbs-placebo arm: Participants will receive a single infusion of normal saline and thereafter a course of PDMC with dihydroartemisinin-piperaquine at 2, 6, and 10 weeks post-discharge

Drug: Dihydroartemisinin - Piperaquine (DP); Biological: Placebo mMAB

Interventions

Antimalarial monoclonal antibodies BIOLOGICAL

L9LS Antimalarial monoclonal antibodies (mMAbs)

Also known as: L9LS

Antimalarial monoclonal antibodies (mMAbs) -L9LS + Placebo-PDMC

Dihydroartemisinin - Piperaquine (DP) DRUG

Post-Discharge Malaria Chemoprevention

Also known as: PDMC

Placebo-mMAB + Malaria chemoprevention- PDMC

Placebo mMAB BIOLOGICAL

Placebo anti malarial monoclonal antibody (placebo mMAB) which is Normal saline

Also known as: Normal Saline

Placebo-mMAB + Malaria chemoprevention- PDMC

Placebo PDMC DRUG

Placebo PDMC course which comprises placebo DP oral tablets

Also known as: Placebo DP

Antimalarial monoclonal antibodies (mMAbs) -L9LS + Placebo-PDMC

Eligibility Criteria

• Age: Up to 9 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17)

You may qualify if:

• Aged \<10 years of both sexes
• Severe anaemia or severe malaria: Initially hospitalised with haemoglobin \<5.0 g/dl or PCV \<15%, or requirement for blood transfusion for other clinical reasons on or during admission to the hospital, or severe malaria, defined as a requirement for parenteral artesunate in the opinion of the treating clinician and the presence of microscopy or RDT confirmed Plasmodium infection
• Resident in catchment area
• Eligibility criteria for enrolment
• Fulfilled the pre-study screening eligibility criteria
• Post-transfusion haemoglobin \>=5.0 g/dl or PCV \>=15%
• Clinically stable, able to take oral medication, able to feed (for breastfeeding children) or eat (for older children) and able to sit unaided (for older children who were already able to do so before hospitalisation)

You may not qualify if:

• Recognised specific other causes of severe anaemia (i.e., trauma, haematological malignancy, known bleeding disorders, such as haemophilia)
• Sickle cell anaemia/sickle cell disease
• Body weight \<5 kg
• HIV infection or on daily cotrimoxazole prophylaxis
• Previous enrolment in the present study
• Children who are scheduled to receive any of the four doses of the malaria vaccine within 6 months after enrolment.
• Received any RTS,S or R21 malaria vaccine primary series or booster dose within the last 14 days inclusive
• On or eligible for cotrimoxazole prophylaxis for HIV infection or HIV exposure
• Children with sickle cell disease because they are eligible for daily proguanil
• Known hypersensitivity to artemether-lumefantrine or dihydroartemisinin-piperaquine
• Anticipated to reside for more than 1 month of the 6-month (26 weeks) intervention period outside of the catchment area (e.g. boarding school)
• Use or known need at enrolment for concomitant prohibited medication during the first 6 months post-discharge
• Ongoing or planned participation in another clinical trial involving ongoing or scheduled treatment with prohibited medicinal products or active follow-up during the first 26 weeks post-discharge
• A known need at the time of enrolment for scheduled surgery during the first 6 months post-discharge
• Suspected non-compliance with the follow-up schedule and protocol in the opinion of the investigator

Sponsors & Collaborators

• Liverpool School of Tropical Medicine: lead
• National Institute of Allergy and Infectious Diseases (NIAID): collaborator
• Centers for Disease Control and Prevention: collaborator

Study Sites (2)

HomaBay County Teaching and Referral Hospital

Kisumu, Nyanza, 40300, Kenya

RECRUITING

Siaya County Referral Hospital

Kisumu, Nyanza, 40600, Kenya

RECRUITING

MeSH Terms

Conditions

Malaria; Anemia

Interventions

Saline Solution

Condition Hierarchy (Ancestors)

Protozoan Infections; Parasitic Diseases; Infections; Mosquito-Borne Diseases; Vector Borne Diseases; Hematologic Diseases; Hemic and Lymphatic Diseases

Intervention Hierarchy (Ancestors)

Crystalloid Solutions; Isotonic Solutions; Solutions; Pharmaceutical Preparations

Study Officials

• Feiko O Ter Kuile, MD, PhD

  Liverpool School of Tropical Medicine

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Mary I Otiti, BSc. MBChB, MSc.

CONTACT

+254 724007076; iwaret.otiti@lstmed.ac.uk

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: PREVENTION
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Model Details: Experimental Arm: mMAbs Participants will receive the antimalarial monoclonal antibody L9LS Administration: Intravenous (IV) infusion Dosage: 30 mg/kg (calculated with 1 kg weight increments) Schedule: Single dose at enrollment Those in the experimental arm will also receive placebo PDMC treatment instead of standard antimalarial medication, 2 weeks after discharge Control Arm: Placebo-mMAbs with Standard PDMC Participants will not receive the L9LS monoclonal antibody but will receive placebo (normal saline) Intravenously. PDMC: Will receive three courses of monthly post-discharge malaria chemoprevention following WHO guidelines PDMC Medication: Dihydroartemisinin-piperaquine (DP) PDMC Schedule: Administered at 2, 6, and 10 weeks post-hospital discharge

Study Record Dates

• First Submitted: June 24, 2025
• First Posted: July 24, 2025
• Study Start: May 2, 2025
• Primary Completion (Estimated): September 30, 2026
• Study Completion (Estimated): April 1, 2027
• Last Updated: July 24, 2025

Record last verified: 2025-07

Data Sharing

• IPD Sharing: Will share
• Shared Documents: STUDY PROTOCOL
• Time Frame: No later than 3 months after the publication of the trial
• Access Criteria: Before publication, a request to the investigators will be required and completion of data sharing request will be needed. After publication, any interested professional will have access to the data that will be made available

Locations

KE (2)